INO: Bathi resik saben saham sajrone 12 wulan pungkasan Inovio

The net income per share trend, where the indicator value reaches -0.80, illustrates Inovio Pharmaceuticals (INO) transitioning toward the commercialization of its first DNA vaccine and the anticipation of the FDA verdict. Stable demand for the drugs is offset by risks of disruptions in Asian component supplies. Meanwhile, outsourcing production and testing to third-party contractors allows the company to focus on developing innovative medicines.

This metric is calculated by dividing the aggregate net income over the last four quarters by the total number of shares, determining the actual equity value of the business. For Inovio Pharmaceuticals (INO), which is completing its DNA therapy development cycle, the rolling annual earnings per share serves as an indicator of the transition from costly research to commercial implementation, where any positive momentum on the chart confirms the financial maturity of the pipeline.